vs
Side-by-side financial comparison of NORTH EUROPEAN OIL ROYALTY TRUST (NRT) and PLUS THERAPEUTICS, INC. (PSTV). Click either name above to swap in a different company.
NORTH EUROPEAN OIL ROYALTY TRUST is the larger business by last-quarter revenue ($2.2M vs $1.4M, roughly 1.6× PLUS THERAPEUTICS, INC.). NORTH EUROPEAN OIL ROYALTY TRUST runs the higher net margin — 87.2% vs -417.9%, a 505.1% gap on every dollar of revenue. On growth, NORTH EUROPEAN OIL ROYALTY TRUST posted the faster year-over-year revenue change (329.5% vs -3.2%).
North European Oil Royalty Trust is a publicly traded royalty trust holding overriding royalty interests in North Sea oil and gas producing properties. It earns revenue from its assets' production sales, distributing nearly all net income to unitholders regularly, with no active drilling or exploration operations.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
NRT vs PSTV — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2M | $1.4M |
| Net Profit | $1.9M | $-5.7M |
| Gross Margin | — | — |
| Operating Margin | — | -420.0% |
| Net Margin | 87.2% | -417.9% |
| Revenue YoY | 329.5% | -3.2% |
| Net Profit YoY | 581.3% | -46.4% |
| EPS (diluted) | — | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.2M | — | ||
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | $519.4K | $1.1M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $1.3M |
| Q1 26 | $1.9M | — | ||
| Q4 25 | — | $-5.7M | ||
| Q3 25 | — | $-4.4M | ||
| Q2 25 | — | $5.2M | ||
| Q1 25 | $285.5K | $-17.4M | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | — | $-2.9M | ||
| Q2 24 | — | $-2.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | -420.0% | ||
| Q3 25 | — | -320.8% | ||
| Q2 25 | — | -110.6% | ||
| Q1 25 | — | -333.9% | ||
| Q4 24 | — | -276.2% | ||
| Q3 24 | — | -260.9% | ||
| Q2 24 | — | -289.1% |
| Q1 26 | 87.2% | — | ||
| Q4 25 | — | -417.9% | ||
| Q3 25 | — | -316.6% | ||
| Q2 25 | — | 370.6% | ||
| Q1 25 | 55.0% | -1643.2% | ||
| Q4 24 | — | -276.4% | ||
| Q3 24 | — | -197.4% | ||
| Q2 24 | — | -229.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.95 | ||
| Q3 25 | — | $-0.04 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $-1.19 | ||
| Q4 24 | — | $-0.51 | ||
| Q3 24 | — | $-0.37 | ||
| Q2 24 | — | $-0.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.9M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $4.0M |
| Total Assets | $3.9M | $16.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $3.9M | — | ||
| Q4 25 | — | $8.6M | ||
| Q3 25 | — | $16.6M | ||
| Q2 25 | — | $6.9M | ||
| Q1 25 | — | $9.9M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.8M | ||
| Q2 24 | — | $8.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $4.0M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $-23.6M | ||
| Q4 24 | — | $-8.9M | ||
| Q3 24 | — | $-5.2M | ||
| Q2 24 | — | $-7.6M |
| Q1 26 | $3.9M | — | ||
| Q4 25 | — | $16.3M | ||
| Q3 25 | — | $18.7M | ||
| Q2 25 | — | $10.3M | ||
| Q1 25 | — | $12.1M | ||
| Q4 24 | — | $6.6M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | — | $11.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-6.3M |
| Free Cash FlowOCF − Capex | — | $-6.3M |
| FCF MarginFCF / Revenue | — | -459.9% |
| Capex IntensityCapex / Revenue | — | 2.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-20.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-2.5M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $-1.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | -459.9% | ||
| Q3 25 | — | -184.3% | ||
| Q2 25 | — | -417.6% | ||
| Q1 25 | — | -583.1% | ||
| Q4 24 | — | -86.5% | ||
| Q3 24 | — | -253.7% | ||
| Q2 24 | — | -96.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 6.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.13× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
